Late-breaking oral presentation to highlight AlloNK + rituximab clinical responses comparable to autologous CAR T-cell therapy in 31 patients ...
Initial clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial, with no ...
Interstitial lung disease (ILD) causes significant morbidity and mortality in patients with systemic autoimmune rheumatic diseases. Patients at high risk of ILD should be screened using ...
Smithsonian Magazine on MSN
How a revolutionary cancer treatment could reset the immune systems of patients with autoimmune diseases
Hanzlik’s multiple sclerosis was destroying her freedom to live the life she wanted. She gave up her active nursing job for a desk role. Frequent falls made her afraid to carry her grandchildren. She ...
It sounds like alchemy: doctors treating rheumatoid arthritis with the beloved base metal gold. Popularized in the 1920s by French physician Jacques Forestier, injecting gold compounds became a ...
Ahead of World Lupus Day on May 10, new research from the Garvan Institute of Medical Research and UNSW Sydney helps explain ...
BOSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and ...
Our immune system has a dark side: It’s supposed to fight off invaders to keep us healthy. But sometimes it turns traitor and attacks our own cells and tissues. What are called autoimmune diseases can ...
Late-breaking oral presentation to highlight AlloNK + rituximab clinical responses comparable to autologous CAR T-cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results